Orforglipron and the rise of oral GLP-1s

Key takeaways

• Orforglipron is a once-daily oral non-peptide small-molecule GLP-1 receptor agonist. It is structurally and pharmacokinetically different from Rybelsus (oral semaglutide), which is a peptide co-formulated with the absorption enhancer salcaprozate sodium (SNAC) .
• ATTAIN-1 (Wharton 2025 NEJM, n=3,127, 72 weeks) is the Phase 3 obesity trial. Mean body weight reductions were 7.5 percent at 6 mg, 8.4 percent at 12 mg, 11.2 percent at 36 mg, and 2.1 percent on placebo .
• ACHIEVE-1 (Rosenstock 2025 NEJM, n=559, 40 weeks) is the Phase 3 type 2 diabetes trial. Mean HbA1c reductions were 1.24 percentage points at 3 mg, 1.47 at 12 mg, 1.48 at 36 mg, and 0.41 on placebo .
• ATTAIN-MAINTAIN (Aronne 2026 Nature Medicine, n=376, 52 weeks) is the switch-maintenance Phase 3b trial. Adults who finished SURMOUNT-5 on tirzepatide and switched to orforglipron maintained 74.7 percent of their prior weight loss compared with 49.2 percent on placebo. Adults who finished on semaglutide and switched to orforglipron maintained 79.3 percent compared with 37.6 percent on placebo .
• Orforglipron is investigational. It has no FDA-approved label, no approved dose, and is not on the FDA bulk substances list. Comparisons to injectable tirzepatide and semaglutide at peak titration still favor the injectables on absolute weight reduction .

What orforglipron is, and what it is not

Orforglipron is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly. The molecule is a non-peptide small molecule, which is the structural feature that lets it be dosed as a pill without the absorption tricks that peptide-based oral semaglutide needs.

The contrast that matters for readers: Rybelsus (oral semaglutide) is the same peptide as injectable Wegovy and Ozempic, repackaged as a tablet with the absorption enhancer salcaprozate sodium (SNAC). Without SNAC, the gastric environment degrades the peptide before it can be absorbed. With SNAC, a fraction of the dose crosses the gastric mucosa. The Rybelsus label specifies an empty-stomach dose with 4 ounces of water and a 30-minute wait before eating or taking other medications .

Orforglipron is not a peptide and does not use SNAC. It is a small molecule that engages the GLP-1 receptor with conventional oral bioavailability and standard dosing without the empty-stomach and water-volume constraints that the Rybelsus label requires. Conflating the two leads to wrong conclusions about both the dosing experience and the comparative pharmacology.

ATTAIN-1, orforglipron at peak in obesity

ATTAIN-1 (ClinicalTrials.gov NCT05869903) is the Phase 3 obesity trial Eli Lilly built for an FDA filing. It randomized 3,127 adults without diabetes to once-daily oral orforglipron at 6 mg, 12 mg, or 36 mg, or placebo, alongside a lifestyle intervention, for 72 weeks. Eligibility was a body mass index of 30 or higher, or 27 or higher plus a weight-related comorbidity. The primary endpoint was percent change in body weight .

At 72 weeks the mean body weight reductions were 7.5 percent at 6 mg, 8.4 percent at 12 mg, 11.2 percent at 36 mg, and 2.1 percent on placebo. Adverse events were dose-dependent and predominantly gastrointestinal: nausea, diarrhea, vomiting, and constipation, consistent with the GLP-1 class profile .

ACHIEVE-1, the diabetes readout

ACHIEVE-1 (Rosenstock 2025 NEJM, NCT05971940) is the Phase 3 trial in adults with early type 2 diabetes. It randomized 559 participants to once-daily oral orforglipron at 3 mg, 12 mg, or 36 mg, or placebo, for 40 weeks. The primary endpoint was the change in glycated hemoglobin (HbA1c) from baseline .

At 40 weeks the mean HbA1c reductions were 1.24 percentage points at 3 mg, 1.47 at 12 mg, 1.48 at 36 mg, and 0.41 on placebo. The flattening between 12 mg and 36 mg suggests the glycemic effect plateaus at a lower exposure than the weight-loss effect, which is consistent with what is seen in the injectable GLP-1 class .

ATTAIN-MAINTAIN, the switch readout

ATTAIN-MAINTAIN (Aronne 2026 Nature Medicine, ClinicalTrials.gov NCT06584916) is the trial that gives oral GLP-1 a place in the maintenance conversation. It enrolled 376 adults with obesity or overweight plus a weight-related comorbidity who had completed SURMOUNT-5, the head-to-head tirzepatide-versus-semaglutide trial that preceded it (Aronne 2025 NEJM, PMID 40353578). Participants were randomized 3:2 to once-daily oral orforglipron at the maximum tolerated dose (24 or 36 mg) or placebo, with a lifestyle intervention, for 52 weeks .

There were two cohorts. Cohort 1 (n=205) had finished SURMOUNT-5 on tirzepatide. Cohort 2 (n=171) had finished on semaglutide 2.4 mg. The primary endpoint was the percent of prior weight reduction maintained at week 52 .

In the tirzepatide cohort, the orforglipron arm maintained 74.7 percent of the prior weight loss versus 49.2 percent on placebo, an estimated treatment difference of 25.5 percentage points (P less than 0.001). In the semaglutide cohort, the orforglipron arm maintained 79.3 percent versus 37.6 percent on placebo, a treatment difference of 41.7 percentage points (P less than 0.001) .

Comparative efficacy at peak titration

Side-by-side at peak doses, the published trials read as follows: semaglutide 2.4 mg in STEP-1 (Wilding 2021 NEJM, n=1,961, 68 weeks) about 14.9 percent; tirzepatide 15 mg in SURMOUNT-1 (Jastreboff 2022 NEJM, n=2,539, 72 weeks) about 20.9 percent; orforglipron 36 mg in ATTAIN-1 (Wharton 2025 NEJM, n=3,127, 72 weeks) about 11.2 percent .

These four numbers come from four different trials with different populations, comorbidities, durations, and outcome definitions. Reading them as a ranking is a useful first pass, but the magnitudes are not directly comparable until head-to-head trials report. The SURMOUNT-5 trial that fed ATTAIN-MAINTAIN was a head-to-head of tirzepatide and semaglutide, not of orforglipron and the injectables. A direct oral-versus-injectable head-to-head trial is what the field still needs.

One related question is whether the orforglipron dose-response curve was still climbing at 36 mg. The ATTAIN-1 readout showed a smaller gap between 12 mg (8.4 percent) and 36 mg (11.2 percent) than between 6 mg (7.5 percent) and 12 mg, which is consistent with a flattening curve at the top of the studied range. The diabetes-side readout from ACHIEVE-1 shows the same pattern: HbA1c reductions essentially overlap between 12 mg and 36 mg. Both findings suggest that 36 mg is close to where the response plateaus in this molecule, which is part of why oral does not catch injectable on absolute weight loss in these trials .

Adherence, the practical case for oral GLP-1

Adherence is the part of the oral story that is easiest to overstate and hardest to measure cleanly. The strongest published evidence here is general, not orforglipron-specific. A meta-analysis of oral antihyperglycemic agents in type 2 diabetes (Iglay 2015, Current Medical Research and Opinion, PMID 26023805) reported a pooled mean medication possession ratio (a measure of how often refills cover daily dosing) of 75.3 percent. About 67.9 percent of patients reached the conventional 80 percent adherence threshold. Discontinuation rates in randomized trials reached about 31.8 percent, and observational persistence ranged from 41.0 to 81.1 percent .

The honest framing for oral GLP-1: daily oral and weekly injectable medications both have meaningful adherence gaps in chronic disease populations, and the published comparative evidence in obesity specifically is thin. The intuition that pills are easier than weekly injections is not proven; it is a hypothesis that prospective adherence trials will need to test. ATTAIN-MAINTAIN's design partially addresses this by measuring real-world retention of a prior outcome rather than self-reported pill-taking, which is the more useful endpoint .

Regulatory status and compounding posture

Orforglipron is investigational. It has no FDA-approved label, no approved dose, and no approved indication. It is not on the FDA bulk substances list eligible for traditional pharmacy compounding under section 503A. Eli Lilly has signaled a US regulatory submission pathway for orforglipron based on the ATTAIN obesity program and the ACHIEVE diabetes program; no FDA decision has issued at the time of writing.

Pharmacies and online vendors that sell substances labeled as orforglipron are not selling the FDA-investigated drug under any approved framework. The identity, purity, and oral bioavailability of those preparations cannot be assumed from the trial data. The trial readouts discussed in this article were generated with sponsor-manufactured tablets at sponsor-defined doses with full pharmacovigilance; they do not transfer to gray-market preparations.

For research and educational purposes only. Not medical advice. Decisions about any GLP-1-class therapy, including any future oral formulation, belong with a qualified clinician who can review individual medical history, comorbidities, and current medications.

Editorial summary

Orforglipron is the first oral non-peptide GLP-1 to reach a registrational Phase 3 efficacy bar with publication-level data. It does not match injectable tirzepatide or semaglutide on peak weight loss at maximum titration. It does appear to hold onto most of the weight already lost on those injectables, which is a different and arguably more practical question for chronic disease management.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.